Epilepsy Trials

In children and young adults with Dravet syndrome and treatment-resistant convulsive seizures, does adjunctive soticlestat (up to 300 mg BID, weight-adjusted) reduce monthly convulsive seizure frequency compared with placebo?

Does responsive closed-loop stimulation of the centromedian thalamus safely and effectively reduce generalized tonic-clonic seizures in patients with drug-resistant idiopathic generalized epilepsy?

Does preventative vigabatrin started at first epileptiform EEG activity, before clinical seizure onset, improve neurocognitive outcomes and prevent drug-resistant epilepsy in infants with TSC?

Does bexicaserin, a selective 5-HT2C receptor superagonist, safely reduce seizure frequency in adolescents and adults with developmental and epileptic encephalopathies of diverse etiologies?

Does soticlestat, a first-in-class cholesterol 24-hydroxylase (CH24H) inhibitor, reduce major motor drop seizure frequency as adjunctive therapy in patients with Lennox–Gastaut syndrome?

Does MRgLITT preserve cognitive function—especially naming and verbal memory—better than traditional open resection in patients with drug-resistant mesial temporal lobe epilepsy?

Do levetiracetam and brivaracetam differ meaningfully in their adverse event profiles compared to placebo and to each other?

Can eslicarbazepine acetate prevent the development of post-stroke epilepsy in patients at high risk after acute stroke?

Can perampanel monotherapy at 4-8 mg/day provide sustained long-term seizure freedom and acceptable tolerability in adolescent and adult patients with newly diagnosed or currently untreated recurrent focal-onset seizures?

Is intrathecal zorevunersen, an antisense oligonucleotide that up-regulates NaV1.1 sodium channels, safe and associated with clinical improvement in children and adolescents with Dravet syndrome?

Does fenfluramine reduce convulsive seizure frequency in children and young adults with Dravet syndrome who have inadequate seizure control despite current antiepileptic drug therapy?

In pregnant women taking antiseizure medications as monotherapy during the first trimester, what is the risk of major congenital malformations for each specific ASM compared to lamotrigine?

Does immediate antiepileptic drug treatment after a first or early seizures improve long-term seizure outcomes compared to deferring treatment until the patient and clinician agree it is necessary?